SNGX stock: Soligenix Inc. (NASDAQ: SNGX) Targets $500 Million Drug Opportunity!

 Here is the link. 

If late-stage biopharmaceutical company, Soligenix, Inc. (NasdaqCM: SNGX), is not on your trading list, you may be missing an opportunity to take advantage of one of the most undervalued biotech stocks on the NASDAQ. And, with the potential for the company to publish at least two significant Phase III clinical trial updates before the end of 2019, the window of opportunity may be starting to close. Perhaps no one sees that happening more than Zacks Small Cap Research, who put out a note on July 9th that reiterates its 12-month price target on the stock at $8.00 per share, roughly 900% higher than it is today. Moreover, while some may argue that an analyst opinion is a pure speculation, few deny that facts often lead to the truth. And for Soligenix, those facts show a path toward prosperity. Taking into account that SNGX stock is trading at approximately $0.89 per share, investors may be overly discounting a company that has more than $7 million in cash, a robust late-stage clinical pipeline, and an emerging bio-defense program that is showing tremendous growth. Moreover, with two Phase III trials nearing completion, coupled with the more than five other active drug and vaccine development programs, investors may soon take advantage of the disconnect and correct the valuation for this well-positioned company that is targeting treatment markets where there is an unmet medical need. In fact, over the past two weeks, SNGX stock has appreciated by more than 21%, showing that the trend is decidedly bullish.

Furthermore, with cash being the prized asset for small-cap biotechs, SNGX's financial position deserves far more credit. In addition to the approximately $7 million in cash on their balance sheet as of their last quarterly filing, SNGX also benefits from significant government funding, which includes an NIH contract of up to $24.7 million for its ricin vaccine program. However, as much comfort as the balance sheet and available funding provides in terms of demonstrating financial security, it's the strength of its emerging rare disease drug pipeline, the ability of its management team to deliver results, and the growing set of potential near-term catalysts that can create significant shareholder value. And, with SNGX driving value from several independent programs, investors are looking for SNGX to evolve from being a late-stage drug development business into a revenue-generating biotech company with FDA-approved products.